Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Essent Group Promotes David B. Weinstock To CFO

David Weinstock has served as interim Chief Financial Officer since June 28, 2022, and as Vice President and Chief Accounting Officer since 2009.

byBenzinga Newsdesk

March 15, 2023

1 minute read

David Weinstock has served as interim Chief Financial Officer since June 28, 2022, and as Vice President and Chief Accounting Officer since 2009.

SunPower’s Management Transparency & Repositioning As Residential Solar Competitor Gain Analysts’ Confidence

By Anusuya Lahiri

Today, 9:58 AM

Credit Suisse analyst Maheep Mandloi upgraded SunPower Corp (NASDAQ:SPWR) from Underperform to Neutral and cut the price target from $21 to $17.…

SPWR

Marathon Petroleum Q2 EPS $0.67 Beats $0.53 Estimate, Sales $29.83B Beat $21.61B Estimate

By Bill Haddad

Today, 9:58 AM

Marathon Petroleum (NYSE:MPC) reported quarterly earnings of $0.67 per share which beat the analyst consensus estimate of $0.53 by 26.42 percent. This is a 150.38 percent increase over losses of $(1.33) per share from

MPC

$100 Invested In This Stock 15 Years Ago Would Be Worth This Much

By Benzinga Insights

Today, 9:58 AM

Alaska Air Gr (NYSE:ALK) has outperformed the market over the past 15 years by 4.58% on an annualized basis.

ALK

Astellas – Seagen’s PADCEV Wins Full FDA Approval And Expanded Label In Tough-To-Treat Urothelial Cancer

By Vandana Singh

Today, 9:58 AM

The FDA granted full approval and a label expansion for Seagen Inc (NASDAQ:SGEN) – Astellas Pharma Inc’s (OTC:ALPMF) PADCEV to treat patients with advanced or…

ALPMF

Essent Group Promotes David B. Weinstock To CFO

Related Posts

SunPower’s Management Transparency & Repositioning As Residential Solar Competitor Gain Analysts’ Confidence

Marathon Petroleum Q2 EPS $0.67 Beats $0.53 Estimate, Sales $29.83B Beat $21.61B Estimate

$100 Invested In This Stock 15 Years Ago Would Be Worth This Much

Astellas – Seagen’s PADCEV Wins Full FDA Approval And Expanded Label In Tough-To-Treat Urothelial Cancer